Replies to post #268 on Evergreen-Agra Global Investments Inc. (fka EGRN)

[The Rainmaker]

Artepharm Global Announces $10 Million Investment to Erradicate Malaria From East Africa Comoros Islands

Artepharm Global Corp. (the "Company") (OTCBB: ARGC) is pleased to announce that an agreement has been signed between The Qater Foundation, The Chinese Federal Government, and a private syndication with the intent of eradicating Malaria from East Africa's Comoros Islands using the Company's Patented ArteQuick Malaria treatment.

The Comoros Islands are a small chain of islands in East Africa (population 800,000) in which 28% of the residents are infected with Malaria. In 2007 Artepharm with its patented ArteQuick Malaria treatment reduced the Malaria rate on the Comoros Island of Moheli from over 20% of the population to less than 1%. Strict Procedural controls will be deployed with this upcoming trial on the rest of the Comoros Islands with the intent of attracting support from the World Health Organisation to back ArteQuick has the leading Global treatment for Malaria.


The Qater Foundation has invested $5 million in Artepharm's clinical trials to eradicate Malaria on the Comoros Islands. The Qater Foundation is led by Her Highness Sheikah Mozah Bint Al Missned . Through Her Highness's passionate leadership the Qater Foundation is dedicated to Global Learning, Community Engagement, Science and Technology, and Scholarship programs. See Qater Foundation website www.qf.org.qa

The Federal Chinese Government has invested $3 million in Artepharm's clinical trials to eradicate Malaria on the Comoros Islands. The Balance of $2 million has been invested by a syndication of private individuals who wish to remain anonymous.

Malaria is the largest killer on the planet, with the kind support of progressive groups such as the Qater Foundation and the Chinese Government and private investors Artepharm's goal is global eradication of Malaria.

About Artepharm Global

Artepharm Global has acquired the patent and worldwide marketing rights for Artequick®, a natural artemisinin-based anti-malaria drug developed by Artepharm Co. Artepharm Co. is a modern pharmaceutical company involved in R&D and the manufacturing of artemisinin-based anti-malarias and anti-viral traditional Chinese medicines. It was jointly established by a group of experts specializing in the research of Qinghao, commonly known as Artemisia annua.

[The Rainmaker]

Artepharm Announces Joint Venture With Chinese Pharmaceutical Company to Market an Inexpensive and Quick-Acting Malaria Cure

Artepharm Global Corp. (the "Company") (OTCBB: ARGC) (www.artepharmglobal.com) is pleased to announce a joint venture with Artepharm Co. Ltd. (Artepharm China), a mid-sized pharmaceutical and biotech company based in Guangzhou, China, who have successfully developed and patented a drug that is effective as both a malaria cure and prevention method.

The anti-malarial drug, Artequick®, is currently being marketed in 11 countries where the incident rate of malaria is high. This is an affordable four-pill treatment, which is sufficient to both cure and prevent even the latest strains of malaria. For 2009, Artepharm China generated approximately US$1.5 million. Under the terms of the joint venture, Artepharm Global will acquire the global marketing rights and hold the global patents for the drug Artequick®, as well as retain all the revenues generated from continuing sales in exchange for 40 million shares of the Company.

The Artequick® anti-malarial drug was developed as a highbred of Chinese natural medicine and modern western pharmaceutical technology. The active ingredient in Artequick® is artemisinin, a plant that is indigenous to China and has been utilized as malaria treatment since the 1600's. While artemisinin has its roots in traditional Chinese medicine, the Artequick® delivery system was developed using the latest in modern western pharmaceutical technology. This integration of eastern and western medicine is a new approach to developing efficacious drugs and could mark the beginning of a massive shift in the global pharmaceutical industry.

In March 2009, the TV news show Dateline (Australia) aired an 18-minute documentary on Artepharm China's work in eradicating malaria on the island of Moheli, in the Comoros Islands off the east coast of Africa. Just months after the Moheli project was launched in November 2007, the island's malaria infection rate dropped rapidly from 22% to 2%. Within the year leading up to this documentary, there were no deaths attributed to malaria. The full documentary can be viewed at http://www.sbs.com.au/dateline/story/about/id/600026/n/The-Last-Bite

Malaria infects over half a billion people each year and causes 3,000 deaths a day. With over 40% percent of the world's population living in areas where malaria is endemic, the vast majority also living in a state of poverty, the market for an inexpensive malaria cure is immeasurable and Artequick® is an optimal solution. Artepharm Global is positioned to positively alter the effect malaria has on the world today.

About Artepharm Global

Artepharm Global has acquired the patent and worldwide marketing
rights for Artequick®, a natural artemisinin-based anti-malaria drug developed by Artepharm Co. Artepharm Co. is a modern pharmaceutical company involved in R&D and the manufacturing of artemisinin-based anti-malarias and anti-viral traditional Chinese medicines. It was jointly established by a group of experts specializing in the research of Qinghao, commonly known as Artemisia annua.

[The Rainmaker]

That's most of what I have....I found some clinical trials all seemed to verify that ARGC's Artequick gets rid of the malaria. Here's one of them...artemisinin-piperaquine is Artequick btw.

Chin J Integr Med (2009) 15: 189-92.

A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria.
Bookmark and Share

TN Trung, B Tan, D Van Phuc, JP Song

OBJECTIVE: The study aimed to evaluate and compare the efficacy and safety of dihydroartemisinin-piperaquine phosphate (Artekin) and artemisinin-piperaquine (Artequick) in the treatment of uncomplicated falciparum malaria. METHODS: A total of 103 uncomplicated falciparum malaria patients were enrolled and randomly assigned to two groups: 52 cases in the Artequick group, and 51 cases in the Artekin group. The patients in the Artequick group were administered with Artequick, twice in 24 h, whereas the patients in the Artekin group were given Artekin 4 times in 2 days. The mean parasite clearance time, mean fever clearance time, 28-day cure rate and parasite recrudescence rates of the two groups were then compared. RESULTS: The mean parasite clearance time and the mean fever clearance time were 43.2+/-13.9 h and 24.7+/-9.9 h, in the Artequick group, and 36.5+/-17.1 h and 22.7+/-11.2 h, in the Artekin group. In both groups the 28-day cure rate was 100%, and the parasite recrudescence rate was 0. CONCLUSION: Both medicines had high cure rates, low recrudescence rates, and no serious adverse reactions. The administration of Artequick, however, was more convenient and lower incidence of gastrointestinal side effects than that of Artekin, so as to increase the efficacy in the malaria population.

http://www.springerlink.com/content/4g8n37748l814385/